



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:
Kenneth Brasel et al.

Docket No.: 2836-D

Serial No: 09/448,378

Group Art Unit: 1644

Filed: November 23, 1999

CPA Filed: June 28, 2001

For: METHODS OF USING FLT3-LIGAND FOR
AUGMENTING AN IMMUNE RESPONSE
FOR THE TREATMENT OF CANCER

Examiner: P. Gambel

RESPONSE TO RESTRICTION REQUIREMENT

BOX NON FEE

Commissioner for Patents
Washington, D.C. 20231

RECEIVED
NOV 15 2002
TECH CENTER 1600/2900

Sir:


In response to the Office Action mailed October 7, 2002, Applicants hereby elect, without traverse, species A, which is drawn to GM-CSF.

As an aside, species A was elected in the response filed November 9, 2001 (see page 6 of the response).

If the Examiner believes that any issues outstanding could be addressed by way of a telephone conference, the Examiner is invited to telephone the undersigned.

Immunex Corporation
Law Department
51 University Street
Seattle, WA 98101
Telephone: (206) 470-4847

Respectfully submitted,


James Klaniecki
Attorney for Applicants
Reg. No. 38,207

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box Non Fee, Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Date: Apr. 6, 2002

Signed: 
Nanci M. Kertson